Kristine M Schmit1, Mark N Lobato, Simona G Lang, Sherri Wheeler, Newton E Kendig, Sarah Bur. 1. Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia (Drs Schmit and Lobato); CDC/CSTE Applied Epidemiology Fellowship Program, Hartford, Connecticut (Ms Lang); Connecticut Department of Public Health, Hartford, Connecticut (Ms Lang); and Health Services Division, Federal Bureau of Prisons, Washington, District of Columbia (Drs Wheeler and Kendig and Ms Bur).
Abstract
CONTEXT: Correctional facilities provide unique opportunities to diagnose and treat persons with latent tuberculosis infection (LTBI). Studies have shown that 12 weekly doses of isoniazid and rifapentine (INH-RPT) to treat LTBI resulted in high completion rates with good tolerability. OBJECTIVE: To evaluate completion rates and clinical signs or reported symptoms associated with discontinuation of 12 weekly doses of INH-RPT for LTBI treatment. SETTING/PARTICIPANTS: During July 2012 to February 2015, 7 Federal Bureau of Prisons facilities participated in an assessment of 12 weekly doses of INH-RPT for LTBI treatment among 463 inmates. MAIN OUTCOME MEASURES: Fisher exact test was used to assess the associations between patient sociodemographic characteristics and clinical signs or symptoms with discontinuation of treatment. RESULTS: Of 463 inmates treated with INH-RPT, 424 (92%) completed treatment. Reasons for discontinuation of treatment for 39 (8%) inmates included the following: 17 (44%) signs/symptoms, 9 (23%) transfer or release, 8 (21%) treatment refusal, and 5 (13%) provider error. A total of 229 (49.5%) inmates reported experiencing at least 1 sign or symptom during treatment; most frequently reported were fatigue (16%), nausea (13%), and abdominal pain (7%). Among these 229 inmates, signs/symptoms significantly associated with discontinuation of treatment included abdominal pain (P < .001), appetite loss (P = .02), fever/chills (P = .01), nausea (P = .03), sore muscles (P = .002), and elevation of liver transaminases 5× upper limits of normal or greater (P = .03). CONCLUSIONS: The LTBI completion rates were high for the INH-RPT regimen, with few inmates discontinuing because of signs or symptoms related to treatment. This regimen also has practical advantages to aid in treatment completion in the correctional setting and can be considered a viable alternative to standard LTBI regimens.
CONTEXT: Correctional facilities provide unique opportunities to diagnose and treat persons with latent tuberculosis infection (LTBI). Studies have shown that 12 weekly doses of isoniazid and rifapentine (INH-RPT) to treat LTBI resulted in high completion rates with good tolerability. OBJECTIVE: To evaluate completion rates and clinical signs or reported symptoms associated with discontinuation of 12 weekly doses of INH-RPT for LTBI treatment. SETTING/PARTICIPANTS: During July 2012 to February 2015, 7 Federal Bureau of Prisons facilities participated in an assessment of 12 weekly doses of INH-RPT for LTBI treatment among 463 inmates. MAIN OUTCOME MEASURES: Fisher exact test was used to assess the associations between patient sociodemographic characteristics and clinical signs or symptoms with discontinuation of treatment. RESULTS: Of 463 inmates treated with INH-RPT, 424 (92%) completed treatment. Reasons for discontinuation of treatment for 39 (8%) inmates included the following: 17 (44%) signs/symptoms, 9 (23%) transfer or release, 8 (21%) treatment refusal, and 5 (13%) provider error. A total of 229 (49.5%) inmates reported experiencing at least 1 sign or symptom during treatment; most frequently reported were fatigue (16%), nausea (13%), and abdominal pain (7%). Among these 229 inmates, signs/symptoms significantly associated with discontinuation of treatment included abdominal pain (P < .001), appetite loss (P = .02), fever/chills (P = .01), nausea (P = .03), sore muscles (P = .002), and elevation of liver transaminases 5× upper limits of normal or greater (P = .03). CONCLUSIONS: The LTBI completion rates were high for the INH-RPT regimen, with few inmates discontinuing because of signs or symptoms related to treatment. This regimen also has practical advantages to aid in treatment completion in the correctional setting and can be considered a viable alternative to standard LTBI regimens.
Authors: S Bur; J E Golub; J A Armstrong; K Myers; B H Johnson; D Mazo; J F Fielder; H Rutz; G Maltas; R McClain; W A Cronin; N G Baruch; L F Barker; W Benjamin; T R Sterling Journal: Int J Tuberc Lung Dis Date: 2003-12 Impact factor: 2.373
Authors: Mary C White; Jacqueline P Tulsky; Enrique Menendez; Joe Goldenson; L Masae Kawamura Journal: Am J Prev Med Date: 2005-11 Impact factor: 5.043
Authors: Timothy R Sterling; M Elsa Villarino; Andrey S Borisov; Nong Shang; Fred Gordin; Erin Bliven-Sizemore; Judith Hackman; Carol Dukes Hamilton; Dick Menzies; Amy Kerrigan; Stephen E Weis; Marc Weiner; Diane Wing; Marcus B Conde; Lorna Bozeman; C Robert Horsburgh; Richard E Chaisson Journal: N Engl J Med Date: 2011-12-08 Impact factor: 91.245
Authors: E E Bliven-Sizemore; T R Sterling; N Shang; D Benator; K Schwartzman; R Reves; J Drobeniuc; N Bock; M E Villarino Journal: Int J Tuberc Lung Dis Date: 2015-09 Impact factor: 2.373
Authors: Iacopo Baussano; Brian G Williams; Paul Nunn; Marta Beggiato; Ugo Fedeli; Fabio Scano Journal: PLoS Med Date: 2010-12-21 Impact factor: 11.069
Authors: Roque Miramontes; Andrew N Hill; Rachel S Yelk Woodruff; Lauren A Lambert; Thomas R Navin; Kenneth G Castro; Philip A LoBue Journal: PLoS One Date: 2015-11-04 Impact factor: 3.240
Authors: Rebekah J Stewart; Kala M Raz; Scott P Burns; J Steve Kammerer; Maryam B Haddad; Benjamin J Silk; Jonathan M Wortham Journal: Am J Public Health Date: 2022-08 Impact factor: 11.561
Authors: G G Alvarez; D Van Dyk; R Mallick; S Lesperance; P Demaio; S Finn; S Edmunds Potvin; M Patterson; C Pease; K Amaratunga; C Hui; D W Cameron; S Mulpuru; S D Aaron; F Momoli; A Zwerling Journal: Int J Circumpolar Health Date: 2020-12 Impact factor: 1.228